Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio discusses the positive data from lead program, SENTI-202, recently presented at the American Association for Cancer Research (AACR) Annual Meeting 2025 Watch the “What This Means” segment here SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its ...

Live video webcast presentation on Thursday, May 8th at 1:00 PM ET Presentation will highlight the recently announced positive preliminary clinical results of lead program, SENTI-202, in the treatment of patients with Relapsed/Refractory AML SOUTH SAN FRANCISCO, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Senti Biosciences, Inc. (“Senti” or the “Company”) (NASDAQ: SNTI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Senti and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 28 ...

Summary of Senti Biosciences Senti-two zero two Clinical Update Conference Call Company and Industry - **Company**: Senti Biosciences - **Industry**: Biotechnology, specifically focused on cell therapy for hematological malignancies, particularly Acute Myeloid Leukemia (AML) Core Points and Arguments 1. **Introduction of Senti-two zero two**: Senti Biosciences is developing SENTI-two zero two, a logic gated CAR NK cell therapy targeting relapsed/refractory AML and related hematological cancers, with promising preliminary results from a Phase one trial [6][7][40]. 2. **Mechanism of Action**: The therapy utilizes a unique logic gate technology that allows for precise targeting of cancer cells while sparing healthy cells, addressing the challenge of heterogeneous cancer cell populations [8][10][14]. 3. **Patient Demographics**: AML affects approximately 21,000 patients annually in the U.S., with a high relapse rate and poor prognosis, highlighting the urgent need for effective therapies [11][12]. 4. **Trial Design**: The Phase one trial is a multi-center, open-label study enrolling adult patients aged 18-75 with relapsed/refractory AML, focusing on safety, maximum tolerated dose (MTD), and efficacy [19][20]. 5. **Dosing and Administration**: The trial evaluates two dose levels of 1 billion and 1.5 billion CAR NK cells, administered in either three or five doses following lymphodepletion [22][23]. 6. **Safety Profile**: Preliminary safety data indicate that SENTI-two zero two is well tolerated, with no dose-limiting toxicities reported and adverse events primarily being hematologic in nature [26][29][40]. 7. **Efficacy Results**: Five out of seven patients achieved an overall response rate (ORR), with four achieving complete remission (CR), indicating promising efficacy in a heavily treated patient population [30][31][40]. 8. **Durability of Response**: All CR patients were minimal residual disease (MRD) negative, with ongoing responses and a median duration of response not yet reached [31][34][41]. 9. **Future Directions**: The company plans to expand the trial to include more patients and potentially explore other malignancies expressing CD33 or FLT3, such as MDS [49][62]. Other Important but Possibly Overlooked Content 1. **Logic Gate Technology**: The logic gate mechanism allows for the recognition of multiple cancer antigens, enhancing the therapy's ability to target diverse cancer cell populations [9][10]. 2. **Patient Characteristics**: The trial population had multiple adverse prognostic factors, including rapid failure of prior therapies and adverse genetic characteristics, underscoring the high unmet need in this patient group [24][25][34]. 3. **Comparison with Existing Therapies**: Current standard care for relapsed/refractory AML shows low response rates (15-25% for CR), emphasizing the need for innovative therapies like SENTI-two zero two [12][65]. 4. **Potential for Outpatient Use**: Given the favorable safety profile of NK cells, there are plans to develop SENTI-two zero two for outpatient administration [50]. 5. **Broader Applications**: The technology has potential applications beyond AML, including solid tumors, which could significantly expand its therapeutic reach [60][61]. This summary encapsulates the key points discussed during the conference call, highlighting the innovative approach of Senti Biosciences in addressing a critical need in cancer treatment.

Clinical Trial Results - Senti Bio reported that 5 of 7 evaluable patients achieved an overall response rate (ORR) of 71.4%, including 3 complete remissions (CR) and 1 complete remission with partial hematologic recovery (CRh) in the SENTI-202 trial[1] - All complete remission (cCR) patients in the trial were measurable residual disease (MRD) negative, indicating effective treatment[3] - The Phase 1 study of SENTI-202 is ongoing, with continued enrollment to confirm the preliminary RP2D[4] - Senti Bio is collaborating with Celest Therapeutics to evaluate SENTI-301A in a trial in China, although enrollment has been stopped due to observed dose limiting toxicities[11] - The company plans to present additional data on SENTI-202 at the AACR meeting, highlighting its potential as a treatment for AML[6] Financial Performance - As of March 31, 2025, Senti Bio held cash and cash equivalents of approximately $33.8 million[10] - Research and development expenses for Q1 2025 were $9.3 million, an increase of 5.7% from $8.8 million in Q1 2024[10] - General and administrative expenses decreased to $7.1 million in Q1 2025 from $7.5 million in Q1 2024, primarily due to a reduction in personnel-related expenses[14] - The net loss for the quarter ended March 31, 2025, was $14.1 million, equating to $1.41 per basic and diluted share[14] Strategic Outlook - Senti Bio's growth strategy includes ongoing clinical trials and potential future research and development efforts[18] - The company is currently conducting a Phase 1 clinical trial for SENTI-202, with expectations for data availability and patient dosing timelines[17] - Senti Bio's management emphasizes the uncertainty surrounding future results due to various risks and market conditions[18] Risks and Dependencies - The company acknowledges dependence on third parties for clinical trial activities and GMP manufacturing, which may impact timelines[18] - Macroeconomic factors, including inflation and rising interest rates, are noted as potential risks to business operations[18] - Senti Bio's forward-looking statements are subject to change based on subsequent events and developments[18] Communication and Investor Relations - The company encourages stakeholders to review information posted on its website and social media for material updates[19] - Senti Bio's communication strategy includes regular updates through its website and social media platforms[19] - The company has not committed to updating forward-looking statements unless required by law[18] - Investor inquiries can be directed to JTC Team, LLC for further information[20]

SOUTH SAN FRANCISCO, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that it will host a conference call and webcast to discuss the new SENTI-202 Phase 1 clinical data being presented at the American Association for Cancer Research (AACR) Annual Meeting on Monday, April 28, 2025 at 8:30 AM ET. ...

Company Overview - Senti Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation cell and gene therapies using its proprietary Gene Circuit platform [2][4] - The company aims to create therapies that enhance precision and control in targeting cancer cells while sparing healthy cells [4] Lead Program - Senti Bio's lead program, SENTI-202, targets hematologic cancers by focusing on CD33 and/or FLT3 [4] - SENTI-202 is currently enrolling patients in a Phase I clinical trial, indicating progress in clinical development [4] Research and Development - The company has demonstrated preclinical success with its Gene Circuits in T cells, enabling selective targeting of solid tumors [4] - Senti Bio is advancing its capabilities through partnerships and exploring applications of Gene Circuits in other cell and gene therapy modalities beyond oncology [4] Industry Context - The discussion in the Virtual Investor KOL segment highlighted the current treatment landscape for acute myeloid leukemia (AML) and areas of unmet need [3] - The insights from respected leukemia researcher Stephen Strickland, MD, emphasize the significance of Senti Bio's innovative approach in addressing these unmet needs [3]

Live moderated webcast with members of the Senti Bio management team on Wednesday, April 23rd at 4:00 PM ETSOUTH SAN FRANCISCO, Calif., April 16, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that will participate in the Virtual Investor Closing Bell Series on Wednesday, April 23, 2025 at 4:00 PM ET. As part o ...

Industry leader in the development and application of cellular therapies, including CAR NK products, for cancer Led development of multiple clinical candidates from conception through IND and early clinical development Vast experience in technology licensing, correlation from “bench to bedside” and back and execution of scientific strategy SOUTH SAN FRANCISCO, Calif., April 10, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology com ...

Company advancing off-the-shelf CAR-NK cell therapy programs for oncology indications with lead candidate, SENTI-202, in clinical development for the treatment of acute myeloid leukemia (AML) Connect with the Company on Webull here SOUTH SAN FRANCISCO, Calif., April 07, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today anno ...